Oncology · AntiemeticRegulatory Approvalregulatorymid-term

Fresenius Kabi's Ondansetron Hydrochloride ANDA076974 Receives AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 6:31:22 PM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The approval status for Fresenius Kabi's Ondansetron Hydrochloride could significantly impact the competitive landscape in the oncology supportive care market. This development highlights the importance of monitoring generic drug approvals as they can shift market dynamics and pricing strategies. Regulatory context from FDA (FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 28 ranked evidence items (10 high-relevance).

Strategic Assessment

Strategic focus on expanding the portfolio of generic oncology supportive care medications could be beneficial for Fresenius Kabi. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Oncology · Antiemetic, 8 regulatory and 6 competitive items passed relevance filtering for Ondansetron Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval status may enhance Fresenius Kabi's position in the oncology supportive care market, competing with existing ondansetron products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL) (FDA). Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda).

Key Risks

Elevated medium regulatory exposure for Ondansetron Hydrochloride could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Fresenius Kabi's entry into the market with a generic version of ondansetron could affect pricing and market share for existing products, potentially leading to increased competition and reduced revenues for incumbents.
Upside for Ondansetron Hydrochloride may improve if Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. (PubMed) delivers favorable follow-through.
Strategic focus on expanding the portfolio of generic oncology supportive care medications could be beneficial for Fresenius Kabi.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market entry timeline for Ondansetron Hydrochloride.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — REMIFENTANIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Teva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Sugammadex Sodium ANDA219448 by Fresenius Kabi
Humanexa Signalsmedium relevance
Moderate corpus alignment
Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Ondansetron Hydrochloride

Commercial impact

medium

Fresenius Kabi's entry into the market with a generic version of ondansetron could affect pricing and market share for existing products, potentially leading to increased competition and reduced revenues for incumbents.

Regulatory impact

medium

The Abbreviated New Drug Application (ANDA) approval status indicates a step towards market entry, but final approval and compliance with regulatory standards remain critical for successful commercialization.

What to watch

Monitor for the final approval and market entry timeline for Ondansetron Hydrochloride.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.